CA2083360A1 - Tri-arginine insulins - Google Patents

Tri-arginine insulins

Info

Publication number
CA2083360A1
CA2083360A1 CA002083360A CA2083360A CA2083360A1 CA 2083360 A1 CA2083360 A1 CA 2083360A1 CA 002083360 A CA002083360 A CA 002083360A CA 2083360 A CA2083360 A CA 2083360A CA 2083360 A1 CA2083360 A1 CA 2083360A1
Authority
CA
Canada
Prior art keywords
arg
tri
proinsulin
insulin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002083360A
Other languages
English (en)
French (fr)
Inventor
James A. Hoffmann
Peter K. Lambooy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2083360A1 publication Critical patent/CA2083360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002083360A 1991-11-26 1992-11-19 Tri-arginine insulins Abandoned CA2083360A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80116391A 1991-11-26 1991-11-26
US07/801,163 1991-11-26

Publications (1)

Publication Number Publication Date
CA2083360A1 true CA2083360A1 (en) 1993-05-27

Family

ID=25180362

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002083360A Abandoned CA2083360A1 (en) 1991-11-26 1992-11-19 Tri-arginine insulins

Country Status (17)

Country Link
US (2) US5491216A (enExample)
EP (1) EP0544466A1 (enExample)
JP (1) JP3304442B2 (enExample)
KR (1) KR930009591A (enExample)
CN (1) CN1072723A (enExample)
AU (1) AU2857692A (enExample)
BR (1) BR9204542A (enExample)
CA (1) CA2083360A1 (enExample)
CZ (1) CZ342492A3 (enExample)
FI (1) FI925343L (enExample)
HU (2) HU9203688D0 (enExample)
IL (1) IL103849A0 (enExample)
MX (1) MX9206724A (enExample)
NO (1) NO924525L (enExample)
NZ (1) NZ245170A (enExample)
TW (1) TW224471B (enExample)
ZA (1) ZA928916B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026218A1 (en) * 1995-02-20 1996-08-29 Amrad Operations Pty. Ltd. Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
EP0821006B1 (de) * 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6689747B2 (en) 2000-03-24 2004-02-10 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
JP2005519041A (ja) * 2001-12-20 2005-06-30 イーライ・リリー・アンド・カンパニー 長期作用を備えたインスリン分子
US20060217290A1 (en) * 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
US8343914B2 (en) * 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
WO2008043033A2 (en) * 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009129250A2 (en) * 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
NZ588857A (en) * 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
NZ600477A (en) 2009-12-11 2014-07-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
CN103533952B (zh) * 2011-03-15 2017-02-15 诺沃—诺迪斯克有限公司 包含半胱氨酸置换的人胰岛素类似物和衍生物
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
BR112016007166A2 (pt) 2013-10-07 2017-09-12 Novo Nordisk As derivado de um análogo de insulina
CN104017809A (zh) * 2014-06-05 2014-09-03 山东省农业科学院生物技术研究中心 改造的人Insulin蛋白表达基因及表达方法
CA2961037A1 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
KR20170036643A (ko) * 2015-09-24 2017-04-03 한미약품 주식회사 인슐린의 제조 방법
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
US4569791A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US4569792A (en) * 1984-06-14 1986-02-11 Eli Lilly And Company Anti-diabetic compounds
US4581165A (en) * 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
ZA877505B (en) * 1986-10-14 1989-05-30 Lilly Co Eli Process for transforming a human insulin precursor to human insulin
US4992418A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogue-[10-Aspartic Acid-B]Human Insulin
ATE101620T1 (de) * 1988-06-23 1994-03-15 Hoechst Ag Mini-proinsulin, seine herstellung und verwendung.
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5130236A (en) * 1989-12-07 1992-07-14 Eli Lilly And Company Process for producing des(64,65)-proinsulin
US5139716A (en) * 1990-02-20 1992-08-18 Loral Aerospace Corp. Method of fabricating coolable ceramic structures

Also Published As

Publication number Publication date
IL103849A0 (en) 1993-04-04
ZA928916B (en) 1994-05-18
NO924525D0 (no) 1992-11-24
FI925343A0 (fi) 1992-11-25
NZ245170A (en) 1994-07-26
CN1072723A (zh) 1993-06-02
BR9204542A (pt) 1993-06-01
US5698669A (en) 1997-12-16
JP3304442B2 (ja) 2002-07-22
EP0544466A1 (en) 1993-06-02
HUT63457A (en) 1993-08-30
KR930009591A (ko) 1993-06-21
MX9206724A (es) 1993-05-01
US5491216A (en) 1996-02-13
AU2857692A (en) 1993-05-27
NO924525L (no) 1993-05-27
FI925343A7 (fi) 1993-05-27
HU9203688D0 (en) 1993-03-29
CZ342492A3 (en) 1993-06-16
JPH05286998A (ja) 1993-11-02
TW224471B (enExample) 1994-06-01
FI925343L (fi) 1993-05-27

Similar Documents

Publication Publication Date Title
US5698669A (en) Tri-arginine insulins
FI79786B (fi) Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes.
US5986048A (en) Process for obtaining insulin precursors having correctly bonded cystine bridges
JP3129722B2 (ja) 新規インスリン誘導体
CA1341638C (en) Fibroblast growth factor
EP0383472A2 (en) Insulin analogs
US20020160938A1 (en) Covalently bridged insulin dimers
US20100210815A1 (en) Insulin production methods and pro-insulin constructs
JPH0357119B2 (enExample)
CN101970476A (zh) 具有超延迟时效特征的新型胰岛素衍生物
US20030104981A1 (en) Human insulin analogues
CA2084061A1 (en) Growth hormone releasing factor analogs
JPH0691834B2 (ja) インシュリン誘導体の製法
JP2001521004A (ja) 脂肪酸−アシル化インスリン類似体
HU201097B (en) Process for producing human insulin derivatives and long-acting pharmaceutical compositions comprising same
US5622932A (en) IGF-1 superagonists
WO1996004307A1 (en) Aspb1 insulin analogs
US5432261A (en) Motlin-like polypeptide and use thereof
HU206375B (en) Process for producing biologically active, stable somatotropins and pharmaceutical compositions comprising same as active ingredient
HU205145B (en) Process for producing new superactive insulin analogs and pharmaceutical compositions comprising same as active ingredient
EP0605983A2 (en) Insulin analogs
EP0613904A2 (en) Vasoactive intestinal peptide analogs for treating smooth muscle disorders and/or asthma
EP0087238A1 (en) Am improved method for preparing human insulin from non-human insulin
WO1992021700A1 (en) Novel calcitonin, and production and use thereof
EP0519750A2 (en) Insulin analogs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued